Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study

被引:7
|
作者
Peng, Duanyang [1 ,2 ]
Liang, Pingan [1 ,2 ]
Zhong, Congying [1 ,2 ]
Xu, Peng [1 ,2 ]
He, Yanqing [3 ]
Luo, Yuxi [1 ,2 ]
Wang, Xia [1 ,2 ]
Liu, Anwen [1 ,2 ,4 ]
Zeng, Zhimin [1 ,2 ,4 ]
机构
[1] Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Jiangxi, Peoples R China
[2] Jiangxi Key Lab Clin Translat Canc Res, Nanchang, Jiangxi, Peoples R China
[3] Nanchang Univ, Dept Nosocomial Infect Control, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[4] Nanchang Univ, Radiat Induced Heart Damage Inst, Nanchang, Jiangxi, Peoples R China
关键词
Non-small cell lung cancer; EGFR amplification; Tyrosine kinase inhibitors; Progression-free survival; EGFR mutation; TYROSINE KINASE INHIBITOR; PHASE-III; OPEN-LABEL; MUTATIONS; GEFITINIB; SURVIVAL; CHEMOTHERAPY; 1ST-LINE; IMPACT; ADENOCARCINOMA;
D O I
10.1186/s12885-022-10390-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epidermal growth factor receptor (EGFR) amplification refers to the copy number increase of EGFR gene, and is often identified as a "bypass " way of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKI) resistance. We aimed to explore the effect of EGFR amplification on EGFR mutation treatmentnaive advanced non-squamous non-small cell lung cancer (NSCLC) patients.Methods: We conducted a prospective observational study in single center, enrolling advanced non-squamous NSCLC patients receiving Tyrosine kinase inhibitors (TKIs) between March 3, 2019, and February 1, 2022. Next-generation sequencing (NGS) was used to detect genetic alterations in tumor tissue samples. Progression-free survival (PFS) curves were performed using the Kaplan-Meier method. Univariate and multivariate analyses were used to evaluate factors affecting the efficacy of TKIs.Results: A total of 117 treatmentnaive advanced NSCLC patients were identified in this study. EGFR amplification was found in 22 of 117 (18.8%) patients with EGFR mutations. Of 22 patients with EGFR amplification, 10 patients harbored EGFR 19 del, 11 patients with 21-L858R. The median follow-up time was 22.47 months. The median PFS of the patients with or without EGFR amplification was 8.25 months and 10.67 months, respectively (log-rank test, P = 0.63). In multivariate analysis, EGFR amplification was not an independent prognosis factor for the patients receiving first-line TKIs [HR = 1.38, 95%CI (0.73-2.58), P = 0.321]. Subgroup analysis revealed that EGFR amplification is a risk factor for progression in the brain metastasis population. [HR = 2.28, 95%CI (1.01, 5.14), P = 0.047].Conclusion: EGFR amplification is not an independent prognosis factor for PFS in advanced non-squamous NSCLC patients receiving first-line TKIs. However, it is an independent risk factor for PFS in the brain metastasis population.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [42] First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
    Wu, Yahua
    Du, Bin
    Lv, Chengliu
    Ji, Xiaohui
    Lan, Yanqin
    Yao, Na
    Zhu, Yingjiao
    Lai, Jinhuo
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [43] Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
    Llinas-Quintero, Nestor
    Gonzalez-Hoyos, David
    Yepes, Andres
    Herrera, Diego A.
    Pelaez-Arroyave, Sebastian
    Caicedo-Zamudio, Carlos
    Blanco-Daza, Erick
    Cuello-Lopez, Javier
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
  • [44] EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
    Chen, Chang-Hung
    Chou, Deng-Wei
    Chung, Kuo-Mou
    Chang, Han-Yu
    MEDICINA-LITHUANIA, 2022, 58 (11):
  • [45] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [46] Ischemic stroke in a patient with EGFR-mutated non-small-cell lung cancer after treatment with ramucirumab
    Chen, Guo-Yu
    Cheng, Wen-Chien
    Tu, Chih-Yen
    THORACIC CANCER, 2022, 13 (23) : 3412 - 3414
  • [47] Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study
    Chang, Gee-Chen
    Tseng, Chien-Hua
    Hsu, Kuo-Hsuan
    Yu, Chong-Jen
    Yang, Cheng-Ta
    Chen, Kun-Chieh
    Yang, Tsung-Ying
    Tseng, Jeng-Sen
    Liu, Chien-Ying
    Liao, Wei-Yu
    Hsia, Te-Chun
    Tu, Chih-Yen
    Lin, Meng-Chih
    Tsai, Ying-Huang
    Hsieh, Meng-Jer
    Wu, Wen-Shuo
    Chen, Yuh-Min
    LUNG CANCER, 2017, 104 : 58 - 64
  • [48] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [49] Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
    Rangachari, Deepa
    Yamaguchi, Norihiro
    VanderLaan, Paul A.
    Folch, Erik
    Mahadevan, Anand
    Floyd, Scott R.
    Uhlmann, Erik J.
    Wong, Eric T.
    Dahlberg, Suzanne E.
    Huberman, Mark S.
    Costa, Daniel B.
    LUNG CANCER, 2015, 88 (01) : 108 - 111
  • [50] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14